PLOS ONE | www.plosone.org
September 2014 | Volume 9 | Issue 9 | e103657
dos Santos et al. BMC Public Health 2014, 14:80 http://www.biomedcentral.com/1471-2458/14/80
Research Article
BMC Infectious Diseases 2014, 14:91/1471-2334/14/91
en collaboration avec des experts en santé mentale du Centre Neuro-Psychopathologique de l’Université de Kinshasa (CNPP/UNIKIN)
Eur Respir J 2014; 43: 24–35 | DOI: 10.1183/09031936.00113413
These Guidelines comprise a General Guidelines document that provides the basic parameters of DG ECHO humanitarian health assistance, complemented by specific Technical Guidance in annex.
This document builds on the Background document prepared for the September 4-5, 2014 Consultation. It includes proposed elements to consider during the development of a framework to assist decision-making at global and national level.
The aim of the document is to assist Member States and releva...nt partners in their discussions to identify the best approaches to ensure the accelerated evaluation and use of available or near-term therapies and vaccines for the treatment and prevention of EVD. The document calls for a coordinated effort by the international community to remove unnecessary obstacles towards this goal.
more
Interim Assessement Report
The EMA review was started by the Agency’s Committee for Medicinal Products for Human Use (CHMP) to support decision-making by health authorities. This first interim report includes information on seven experimental medicines intended for the treatment of people infecte...d with the Ebola virus:
BCX4430 (Biocryst);
Brincidofovir (Chimerix);
Favipiravir (Fujifilm Corporation/Toyama);
TKM-100802 (Tekmira);
AVI-7537 (Sarepta);
ZMapp (Leafbio Inc.);
Anti-Ebola F(ab’)2 (Fab’entech).
The amount of information available for the seven treatments is highly variable. For some compounds there is no data from use in human subjects available. A small number of treatments have been administered to patients in the current Ebola outbreak as compassionate use. Finally, there are also medicines included in this review that have already been studied in humans, albeit for the treatment of other viral diseases.
more
Documentation of Best Practices and Bottlenecks to Program Implementation in Senegal
SUMMARY REPORT
Accessed at March 2014
The occurrence of a high percentage of couterfeit medicines on the global medicines market is often attributed to a lack of effective regulation and a weak enforcement capacity. This review, while focusing on counterfeit medicines and medical devices in developing countries, will present information... on their impact and how these issues can be addressed by regulation and control of the supply chain using technology appropriate to the developing world.
more
UNAIDS/WHO Working group
HIV/AIDS and STI surveillance 2015 / Reference
This module introduces the “Vaccinator’s Manual”, a guideline for vaccinators. The aim of the manual is to update EPI guidelines to include all the changes since the third edition of the Vaccinators Manual (2008)